Sanofi Expands Regeneron Alliance With Four Long-Acting Antibodies, Paying $1B Upfront With Up To $7B In Milestones; Costs And Profits Shared Equally

REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, is added to the alliance, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron

Regeneron to receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments; companies to equally share development and commercialization costs, as well as any future profits